156 related articles for article (PubMed ID: 2111239)
1. Insulin and sulphonylurea in the therapy of type 2 diabetes.
Sotaniemi EA; Vierimaa E; Huupponen R; Karvonen I; Vuoti MJ; Rytömaa K
Diabetes Res Clin Pract; 1990 Mar; 8(3):243-51. PubMed ID: 2111239
[TBL] [Abstract][Full Text] [Related]
2. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
Simpson HC; Sturley R; Stirling CA; Reckless JP
Diabet Med; 1990 Feb; 7(2):143-7. PubMed ID: 2137755
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment.
Groop L; Groop PH; Stenman S; Saloranta C; Tötterman KJ; Fyhrquist F; Melander A
Diabetes Care; 1987; 10(6):671-8. PubMed ID: 3123184
[TBL] [Abstract][Full Text] [Related]
4. Glyburide and glipizide in treatment of diabetic patients with secondary failures to tolazamide or chlorpropamide.
Lev JD; Zeidler A; Kumar D
Diabetes Care; 1987; 10(6):679-82. PubMed ID: 3123183
[TBL] [Abstract][Full Text] [Related]
5. Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on lipoprotein metabolism and glucoregulation.
Falko JM; Osei K
Am J Med; 1985 Sep; 79(3B):92-101. PubMed ID: 3931467
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
DeFronzo RA; Goodman AM
N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
[TBL] [Abstract][Full Text] [Related]
8. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
9. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Chow CC; Tsang LW; Sorensen JP; Cockram CS
Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
[TBL] [Abstract][Full Text] [Related]
10. Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy.
Lins PE; Lundblad S; Persson-Trotzig E; Adamson U
Acta Med Scand; 1988; 223(2):171-9. PubMed ID: 3126626
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
Groop L; Wåhlin-Boll E; Groop PH; Tötterman KJ; Melander A; Tolppanen EM; Fyhrqvist F
Eur J Clin Pharmacol; 1985; 28(6):697-704. PubMed ID: 3933984
[TBL] [Abstract][Full Text] [Related]
12. Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism.
Osei K; O'Dorisio TM; Falko JM
Am J Med; 1984 Dec; 77(6):1002-9. PubMed ID: 6439036
[TBL] [Abstract][Full Text] [Related]
13. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.
Erle G; Lovise S; Stocchiero C; Lora L; Coppini A; Marchetti P; Merante D
Acta Diabetol; 1999 Jun; 36(1-2):61-5. PubMed ID: 10436254
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?
Trischitta V; Italia S; Raimondo M; Guardabasso V; Licciardello C; Runello F; Mazzarino S; Sangiorgi L; Anello M; Vigneri R
J Endocrinol Invest; 1998 Dec; 21(11):744-7. PubMed ID: 9972673
[TBL] [Abstract][Full Text] [Related]
15. Conversion from low-dose insulin therapy to glipizide in patients with non-insulin-dependent diabetes mellitus.
Rosenstock J; Meisel A; Raskin P
Am J Med; 1987 Sep; 83(3A):10-5. PubMed ID: 3307402
[TBL] [Abstract][Full Text] [Related]
16. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
Clauson P; Karlander S; Steen L; Efendic S
Diabet Med; 1996 May; 13(5):471-7. PubMed ID: 8737030
[TBL] [Abstract][Full Text] [Related]
17. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
[TBL] [Abstract][Full Text] [Related]
18. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months.
Birkeland KI; Furuseth K; Melander A; Mowinckel P; Vaaler S
Diabetes Care; 1994 Jan; 17(1):45-9. PubMed ID: 8112188
[TBL] [Abstract][Full Text] [Related]
19. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
20. Glibenclamide and glipizide in maturity onset diabetes. A double-blind cross-over study.
Blohmé G; Waldenström J
Acta Med Scand; 1979; 206(4):263-7. PubMed ID: 116480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
